<?xml version="1.0" encoding="UTF-8"?>
<?xml-model href="http://docbook.org/xml/5.1/rng/docbook.rng" schematypens="http://relaxng.org/ns/structure/1.0"?>
<?xml-model href="http://docbook.org/xml/5.1/rng/docbook.rng" type="application/xml" schematypens="http://purl.oclc.org/dsdl/schematron"?>
<book xmlns="http://docbook.org/ns/docbook" xmlns:xlink="http://www.w3.org/1999/xlink" version="5.1">
    <info>
        <title>Clinical Decision Support (CDS) Content and Health Level 7 (HL7)-Compliant Knowledge
            Artifacts (KNARTs)</title>
        <subtitle>Gastroenterology: Hepatitis C Clinical Content White Paper </subtitle>
        <copyright>
            <year>2018</year>
            <holder>B3 Group, Inc.</holder>
        </copyright>
        <legalnotice>
            <title>B3 Group, Inc.</title>
            <para>NOTICE OF GOVERNMENT COPYRIGHT LICENSE AND UNLIMITED RIGHTS LICENSE</para>
            <para>Licensed under the Apache License, Version 2.0 (the "License"); you may not use
                this file except in compliance with the License.</para>
            <para>You may obtain a copy of the License at <link
                    xlink:href="http://www.apache.org/licenses/LICENSE-2.0"
                    >http://www.apache.org/licenses/LICENSE-2.0</link>
            </para>
            <para>Unless required by applicable law or agreed to in writing, software distributed
                under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR
                CONDITIONS OF ANY KIND, either express or implied. See the License for the specific
                language governing permissions and limitations under the License.</para>
            <para>Portions of this content are derivative works from content produced by Cognitive
                Medical Systems, Inc. licensed under the Apache License, Version 2.0.</para>
            <para>Additional portions of this content are derivative works from content contributed
                by Motive Medical Intelligence Inc., under Creative Commons Attribution-ShareAlike
                4.0.</para>
            <para>Contributions from 2013-2018 were performed either by US Government employees, or
                under US Veterans Health Administration contracts.</para>
            <para>US Veterans Health Administration contributions by government employees are work
                of the U.S. Government and are not subject to copyright protection in the United
                States. Portions contributed by government employees are USGovWork (17USC §105). Not
                subject to copyright.</para>
            <para>See: <link xlink:href="https://www.usa.gov/government-works"
                    >https://www.usa.gov/government-works</link>
            </para>
            <para>Contribution by contractors to the US Veterans Health Administration during this
                period are contractually contributed under the Apache License, Version 2.0 and US
                Government sponsorship is acknowledged under Contract VA118-16-D-1008, Task Order
                VA11817F10080007.</para>
        </legalnotice>
        <copyright>
            <year>2018</year>
            <holder>Cognitive Medical Systems, Inc.</holder>
        </copyright>
        <legalnotice>
            <title>Cognitive Medical Systems, Inc.</title>
            <para>Licensed under the Apache License, Version 2.0 (the "License"); you may not use
                this file except in compliance with the License.</para>
            <para>You may obtain a copy of the License at <link
                    xlink:href="http://www.apache.org/licenses/LICENSE-2.0"
                    >http://www.apache.org/licenses/LICENSE-2.0</link>
            </para>
            <para>Unless required by applicable law or agreed to in writing, software distributed
                under the License is distributed on an "AS IS" BASIS, WITHOUT WARRANTIES OR
                CONDITIONS OF ANY KIND, either express or implied. See the License for the specific
                language governing permissions and limitations under the License.</para>
            <para>This and related content produced by Cognitive Medical Systems, Inc. licensed
                under the Apache License, Version 2.0 is available at: <link
                    xlink:href="https://bitbucket.org/cogmedsys/hl7-kas-examples"
                    >https://bitbucket.org/cogmedsys/hl7-kas-examples</link>
            </para>
            <para>Additional portions of this content are derivative works from content contributed
                by Motive Medical Intelligence Inc., under Creative Commons Attribution-ShareAlike
                4.0. <link xlink:href="https://bitbucket.org/cogmedsys/kas-source-material"
                    >https://bitbucket.org/cogmedsys/kas-source-material</link>
            </para>
            <para>Contributions from 2013-2018 were performed either by US Government employees, or
                under US Veterans Health Administration contracts.</para>
            <para>US Veterans Health Administration contributions by government employees are work
                of the U.S. Government and are not subject to copyright protection in the United
                States. Portions contributed by government employees are USGovWork (17USC §105). Not
                subject to copyright. See: <link xlink:href="https://www.usa.gov/government-works"
                    >https://www.usa.gov/government-works</link>
            </para>
            <para>Contribution by contractors to the US Veterans Health Administration during this
                period are contractually contributed under the Apache License, Version 2.0 and US
                Government sponsorship is acknowledged under Contract VA118-16-D-1008-0007.</para>
        </legalnotice>
        <authorgroup>
            <author>
                <personname>Department of Veterans Affairs (VA)</personname>
            </author>
            <author>
                <orgname><inlinemediaobject>
                        <alt>Department of Veterans Affairs Logo</alt>
                        <imageobject>
                            <imagedata fileref="images/VALOGO.jpg"/>
                        </imageobject>
                    </inlinemediaobject></orgname>
            </author>
            <author>
                <orgname>Knowledge Based Systems (KBS)</orgname>
            </author>
            <author>
                <orgname>Office of Informatics and Information Governance (OIIG)</orgname>
            </author>
            <author>
                <orgname>Clinical Decision Support (CDS)</orgname>
            </author>
        </authorgroup>
        <abstract>
            <info>
                <title>Contract: VA118-16-D-1008, Task Order (TO): VA-118-16-F-1008-0007</title>
            </info>
            <para>
                <table frame="all" rowsep="1" colsep="1">
                    <title>Relevant KNART Information: Gastroenterology: Hepatitis C</title>
                    <tgroup cols="2" align="left">
                        <thead>
                            <row valign="bottom">
                                <!--<entry valign="middle">ID</entry>-->
                                <entry valign="middle">KNART Name</entry>
                                <entry valign="middle">Associated CLIN</entry>
                            </row>
                        </thead>
                        <tbody>
                            <row>
                                <!--<entry>B5</entry>-->
                                <entry>Hepatitis C- Consult Request/Documentation Template </entry>
                                <entry>CLIN0005AD</entry>
                            </row>
                            <row>
                                <entry>Hepatitis C- Elbasvir/Grazoprevir- Order Set </entry>
                                <entry>CLIN0004AC</entry>
                            </row>
                            <row>
                                <entry>Hepatitis C- Lediposvir/Sofobuvir- Order Set </entry>
                                <entry>CLIN0004AC</entry>
                            </row>
                            <row>
                                <entry>Hepatitis C- Glecaprevir/Pibrentavir- Order Set </entry>
                                <entry>CLIN0004AC</entry>
                            </row>
                            <row>
                                <entry>Hepatitis C- Composite/Consult Request</entry>
                                <entry>N/A</entry>
                            </row>
                        </tbody>
                    </tgroup>
                </table>
            </para>
        </abstract>
        <pubdate>March 2018</pubdate>
        <volumenum>Version 1.0</volumenum>
        <revhistory>
            <revision>
                <revnumber>1.0</revnumber>
                <date>3/9/2018</date>
                <authorinitials>Jennifer Reed and Steve Mahalec</authorinitials>
                <revremark>Final DocBook transformation</revremark>
            </revision>
            <revision>
                <revnumber>0.10</revnumber>
                <date>3/5/2018</date>
                <authorinitials>Diane Montella</authorinitials>
                <revremark>Final approval from Program Office.</revremark>
            </revision>
            <revision>
                <revnumber>0.9</revnumber>
                <date>12/20/2017</date>
                <authorinitials>Jennifer Reed and Steve Mahalec</authorinitials>
                <revremark>DocBook transformation</revremark>
            </revision>
            <revision>
                <revnumber>0.8</revnumber>
                <date>11/17/2017</date>
                <authorinitials>Ralph Ruocco</authorinitials>
                <revremark>Revised Motive data added</revremark>
            </revision>
            <revision>
                <revnumber>0.7</revnumber>
                <date>10/17/2017</date>
                <authorinitials>Lindsey Birt</authorinitials>
                <revremark>Common Issues and edit</revremark>
            </revision>
            <revision>
                <revnumber>0.6</revnumber>
                <date>9/28/2017</date>
                <authorinitials>Wendelyn Bradley</authorinitials>
                <revremark>Review and edit</revremark>
            </revision>
            <revision>
                <revnumber>0.5</revnumber>
                <date>9/28/2017</date>
                <authorinitials>Lindsey Birt</authorinitials>
                <revremark>Revised Motive data added, updated formatting</revremark>
            </revision>
            <revision>
                <revnumber>0.4</revnumber>
                <date>9/20/2017</date>
                <authorinitials>Lindsey Birt</authorinitials>
                <revremark>Formatting and edits</revremark>
            </revision>
            <revision>
                <revnumber>0.3</revnumber>
                <date>9/15/2017</date>
                <authorinitials>Ralph Ruocco</authorinitials>
                <revremark>Added VA Artifacts</revremark>
            </revision>
            <revision>
                <revnumber>0.2</revnumber>
                <date>9/11/2017</date>
                <authorinitials>Ralph Ruocco</authorinitials>
                <revremark>Motive data added</revremark>
            </revision>
            <revision>
                <revnumber>0.1</revnumber>
                <date>8/17/2017</date>
                <authorinitials>Lindsey Birt</authorinitials>
                <revremark>Initial Draft</revremark>
            </revision>
        </revhistory>
    </info>
    <preface>
        <title>VA Subject Matter Expert (SME) Panel</title>
        <informaltable xml:id="va.SME.List" frame="all">
            <tgroup cols="3">
                <thead>
                    <row>
                        <entry>Name</entry>
                        <entry>Title</entry>
                        <entry>Project Role</entry>
                    </row>
                </thead>
                <tbody>
                    <row>
                        <entry>David Kaplan, MD</entry>
                        <entry>Staff Physician Gastroenterology Philadelphia, PA</entry>
                        <entry>SME, Primary</entry>
                    </row>
                    <row>
                        <entry>Timothy Morgan, MD</entry>
                        <entry>Physician, Long Beach VA Medical Center (VAMC), Long Beach, CA </entry>
                        <entry>SME, Secondary</entry>
                    </row>
                    <row>
                        <entry>James Wilson, MD</entry>
                        <entry>Administrative Specialist, Puget Sound Healthcare System, Seattle,
                            WA</entry>
                        <entry>SME</entry>
                    </row>
                    <row>
                        <entry>Jason Dominitz, MD</entry>
                        <entry>National Director of Gastroenterology, Puget Sound Healthcare System,
                            Seattle, WA </entry>
                        <entry>SME</entry>
                    </row>
                    <row>
                        <entry>Byron Cryer, MD</entry>
                        <entry>Physician, North Texas VA Healthcare System, Dallas, TX</entry>
                        <entry>SME</entry>
                    </row>
                    <row>
                        <entry>Ashley Faulx, MD</entry>
                        <entry>Med-GI Fellow, Louis Stokes Cleveland VAMC, Cleveland, OH</entry>
                        <entry>SME</entry>
                    </row>
                    <row>
                        <entry>Lyn Sue Kahng, MD</entry>
                        <entry>GI Section Chief, Jesse Brown VAMC, Chicago, IL</entry>
                        <entry>SME</entry>
                    </row>
                    
                    <row>
                        <entry>Heiko Pohl, MD</entry>
                        <entry>Physician, White River Junction VAMC, White River Junction, VT </entry>
                        <entry>SME</entry>
                    </row>
                    
                    <row>
                        <entry>Aasma Shaukat, MD</entry>
                        <entry>Physician, Minneapolis VAMC Minneapolis, MN </entry>
                        <entry>SME</entry>
                    </row>
                    <row>
                        <entry>Walter Smalley, MD</entry>
                        <entry>Physician, Tennessee Valley HCS Nashville, TN </entry>
                        <entry>SME</entry>
                    </row>
                    
                    <row>
                        <entry>Pamela (Pam) Belperio</entry>
                        <entry>PharmD/Clinical Pharmacist, Population Health Services Los Angeles,
                            CA </entry>
                        <entry>SME</entry>
                    </row>
                    
                    <row>
                        <entry>Lisa Backus</entry>
                        <entry>Deputy Chief Consultant, Population Health Services Palo Alto, CA </entry>
                        <entry>SME</entry>
                    </row>
                </tbody>
            </tgroup>
        </informaltable>
    </preface>
    <preface>
        <title>Introduction</title>
        <para>The VA is committed to improving the ability of clinicians to provide care for
            patients while increasing quality, safety, and efficiency. Recognizing the importance of
            standardizing clinical knowledge in support of this goal, VA is implementing the HL7
            Knowledge Artifact Specification for a wide range of VA clinical use cases. Knowledge
            Artifacts, referred to as KNARTs, enable the structuring and encoding of clinical
            knowledge so the knowledge can be integrated with electronic health records to enable
            clinical decision support. </para>
        <para>The purpose of this Clinical Content White Paper is to capture the clinical context
            and intent of KNART use cases in sufficient detail to provide the KNART authoring team
            with the clinical source material to construct the corresponding knowledge artifacts
            using the HL7 Knowledge Artifact Specification. This paper has been developed using
            material from a variety of sources: VA artifacts, clinical practice guidelines, evidence
            in the body of medical literature, and clinical expertise. After reviewing these
            sources, the material has been synthesized and harmonized under the guidance of VA
            subject matter experts to reflect clinical intent of this use case for this use
            case.</para>
        <para>Unless otherwise noted, items within this white paper (e.g., documentation template
            fields, orderable items, etc.) are chosen to reflect the clinical intent at the time of
            creation. To provide an exhaustive list of all possible items and their variations is
            beyond the scope of this work. </para>
    </preface>
    <preface version="5.1">
        <info>
            <title>Conventions Used</title>
        </info>
        <para>Conventions used within the knowledge artifact descriptions include:</para>
        <itemizedlist mark="none" spacing="compact">
            <listitem>
                <para>&lt;obtain&gt;: Indicates a prompt to obtain the information listed
                        <itemizedlist mark="bullet" spacing="compact">
                        <listitem>
                            <para>If possible, the requested information should be obtained from the
                                underlying system(s). Otherwise, prompting the user for information
                                may be required</para>
                        </listitem>
                        <listitem>
                            <para>Default Values: Unless otherwise noted, &lt;obtain&gt; indicates
                                to obtain the most recent observation. It is recognized that this
                                default time-frame value may be altered by future
                                implementations</para>
                        </listitem>
                    </itemizedlist></para>
            </listitem>
            <listitem>
                <para>[...]: Square brackets enclose explanatory text that indicates some action on
                    the part of the clinical user, or general guidance to the clinical or technical
                    teams. Examples include, but are not limited to:</para>
                <itemizedlist mark="none" spacing="normal">
                    <listitem>
                        <para>[Begin ...], [End ...]: Indicates the start and end of specific areas
                            to clearly delineate them for technical purposes.</para>
                        <para>[Activate ...]: Initiates another knowledge artifact or knowledge
                            artifact section.</para>
                        <para>[Section Prompt: ...]: If this section is applicable, then the
                            following prompt should be displayed to the user.</para>
                        <para>[Section Behavior: ...]: Indicates technical constraints or
                            considerations for the selection of items outlined in the section
                            prompt.</para>
                        <para>[Attach: ...]: Indicates that the specified item (e.g. procedure or
                            result interpretation) should be attached to the documentation template
                            if available.</para>
                        <para>[Link: ...]: Indicates that rather than attaching an item (e.g.
                            image), a link should be included in the documentation template.</para>
                        <para>[Clinical Comment: ...]: Indicates technical considerations or notes
                            to be utilized for KNART authoring and at time of implementation
                            planning.</para>
                        <para>[Technical Note: ...]: Indicates technical considerations or notes to
                            be utilized for KNART authoring and at time of implementation
                            planning.</para>
                        <para>[If ...]: Indicates the beginning of a conditional section.</para>
                        <para>[Else, ...]: Indicates the beginning of the alternative branch of a
                            conditional section.</para>
                        <para>[End if ...]: Indicates the end of a conditional section.</para>
                    </listitem>
                </itemizedlist>
            </listitem>
            <listitem>
                <para>☐ [Check box]: Indicates items that should be selected based upon the section
                    selection behavior.</para>
            </listitem>
        </itemizedlist>
    </preface>
    <chapter>
        <title>Gastroenterology: Hepatitis C</title>
        <section>
            <title>Clinical Context</title>
            <para>[Begin Clinical Context.]</para>
            <para>Intended to identify patients for whom hepatitis C treatment is recommended;
                facilitate discussion between the primary care provider and the patient regarding
                test results, precautions to prevent further liver damage and disease transmission,
                potential barriers to care, and patient treatment preferences and goals; support
                documentation related to the discussion and pretreatment assessment; and promote
                decision-making and appropriate ordering based on patient- and disease-specific
                factors.</para>
            <table>
                <title>Clinical Context Domains</title>
                <tgroup cols="2">
                    <tbody>
                        <row>
                            <entry>Target User</entry>
                            <entry>Primary Care Physicians, Gastroenterologists</entry>
                        </row>
                        <row>
                            <entry>Patient</entry>
                            <entry>Adult outpatients with chronic Hepatitis C infection</entry>
                        </row>
                        <row>
                            <entry>Priority</entry>
                            <entry>Routine</entry>
                        </row>
                        <row>
                            <entry>Specialty</entry>
                            <entry>Primary Care, Gastroenterologists</entry>
                        </row>
                        <row>
                            <entry>Location</entry>
                            <entry>Outpatient</entry>
                        </row>
                    </tbody>
                </tgroup>
            </table>
            <para>[End Clinical Context.]</para>
        </section>
        <section>
            <title>Knowledge Artifacts</title>
            <para>[Begin Knowledge Artifacts.]</para>
            <para>This section describes the CDS KNARTs that are part of the GI Hepatitis C group,
                and include:</para>
            <itemizedlist mark="none">
                <listitem>
                    <para>Composite/Consult Request: Gastroenterology: Hepatitis C KNART</para>
                    <itemizedlist mark="none">
                        <listitem>
                            <para>High-level, encompassing artifact meant to communicate the request
                                for gastroenterology consultation</para>
                        </listitem>
                        <listitem>
                            <para>Relies upon the documentation template and order set
                                artifacts</para>
                        </listitem>
                    </itemizedlist>
                </listitem>
                <listitem>
                    <para>Consult Request/Documentation Template: Gastroenterology: Hepatitis C
                        KNART</para>
                    <itemizedlist mark="none">
                        <listitem>
                            <para>Documents information provided either by a provider referring to
                                gastroenterology for management of hepatitis C, or by a provider
                                managing a hepatitis C patient himself or herself</para>
                        </listitem>
                        <listitem>
                            <para>Includes logic for appropriate display of documentation
                                sections</para>
                        </listitem>
                    </itemizedlist>
                </listitem>
                <listitem>
                    <para>Order Sets: Gastroenterology: Hepatitis C KNART</para>
                    <itemizedlist mark="none">
                        <listitem>
                            <para>Orderable items associated with the management of hepatitis
                                C</para>
                        </listitem>
                        <listitem>
                            <para>Includes logic for appropriate display of the order set</para>
                        </listitem>
                    </itemizedlist>
                </listitem>
            </itemizedlist>
            <para>[End Knowledge Artifacts.]</para>
        </section>
    </chapter>
    <chapter>
        <title>Composite: Hepatitis C Consult Request</title>
        <para>[Begin Composite.]</para>
        <section>
            <title>Knowledge Narrative</title>
            <para>[Begin Knowledge Narrative.]</para>
            <para>[See Clinical Context in Chapter 1.]</para>
            <para>Hepatitis C is a pervasive, and usually silent, disease with serious implications
                for morbidity and mortality. With the availability of a host of efficacious but
                expensive new drugs, it is imperative that patients be screened and treated for
                hepatitis C according to evidence-based guidelines. Examples include the use of
                ledipasvir/sofosbuvir for hepatitis C genotypes 1, 4, 5, and 6; elbasvir/grazoprevir
                for hepatitis C genotypes 1 and 4; and glecaprevir/pibrentasvir for all hepatitis C
                genotypes (VA October 2017; AASLD/IDSA 2017). In addition to matching the
                appropriate drug combinations to the appropriate genotypes, accounting for
                decompensated liver disease, prior treatments, comorbid conditions, and potential
                drug–drug interactions further complicates rational prescribing. Operationalizing
                such evidence—thus making the right thing to do also the easy thing to do—within the
                VA is particularly important because the complexity of the viral nomenclature and
                indications for pharmacologic therapy can easily overwhelm non-hepatologists.</para>
            <para>[Technical Note: Users should revise the information provided in the documentation
                template—consult request form as needed during the evaluation.]</para>
            <para>[End Knowledge Narrative.]</para>
        </section>
        <section>
            <title>Consult Request</title>
            <para>[Begin Consult Request.]</para>
            <para>Reason for Consult: Treatment recommendation for patient with Chronic Hepatitis
                C</para>
            <para>[Section Prompt: Goal of Consult.]</para>
            <para>[Section Selection Behavior: Required. Select one.]<itemizedlist>
                    <listitem>
                        <para>&#x2610; Return to primary care provider (PCP) for therapy</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Start treatment and return to PCP for follow up and
                            maintenance</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Start treatment, monitor for effect and when on stable
                            therapy return to PCP</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Treat as long as necessary (or indefinitely)</para>
                    </listitem>
                </itemizedlist></para>
            <para>Consult Specialty: Gastroenterology</para>
            <para>Priority: Routine</para>
            <para>&lt;obtain&gt; Referring Physician</para>
            <para>&lt;obtain&gt; Referring Physician Contact Information</para>
            <para>&lt;obtain&gt; Patient Identification</para>
            <para>&lt;obtain&gt; Patient Demographics</para>
            <para>&lt;obtain&gt; Information required by receiving facility</para>
            <para>[End Consult Request.]</para>
            <para>[End Composite.]</para>
        </section>
    </chapter>
    <chapter>
        <title>Consult Request/Documentation Template: Hepatitis C</title>
        <para>[Begin Consult Request/Documentation Template.]</para>
        <para>[Technical Note: Users should enter information into the documentation
            template—consult request form as needed during the evaluation.] </para>
        <section>
            <title>Demographics</title>
            <para>[Begin Demographics.]</para>
            <para>[Technical Note: Pre-populate the Age and Race/Ethnicity.]</para>
            <para>&lt;obtain&gt; Age (Years)</para>
            <para>&lt;obtain&gt; Race/Ethnicity</para>
            <para>[End Demographics.]</para>
        </section>
        <section>
            <title>Problem List</title>
            <para>[Begin Problem List.]</para>
            <para>[Technical Note: Pre-populate the Problem List, providing capability to edit the list.]<itemizedlist mark="none">
                    <listitem>
                        <para>&lt;obtain&gt; Problem List</para>
                    </listitem>
                </itemizedlist></para>
            <para>[End Problem List.]</para>
        </section>
        <section>
            <title>Body Mass Index (BMI)</title>
            <para>[Begin Body Mass Index.]</para>
            <para>[Technical Note: Pre-populated the BMI, providing capability to edit.]</para>
            <para>&lt;obtain&gt; Body Mass Index (BMI) (kg/m^2)</para>
            <para>&lt;obtain&gt; Date BMI determined</para>
            <para>[End Body Mass Index.]</para>
        </section>
        <section>
            <title>Medication List</title>
            <para>[Begin Medication List.]</para>
            <para>[Technical Note: Pre-populate the Medication List, providing capability to edit
                the list.]<itemizedlist mark="none">
                    <listitem>
                        <para>&lt;obtain&gt; Medication List (Including Over-the-Counter Medications
                            and Supplements)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[End Medication List.]</para>
        </section>
        <section>
            <title>History of Present Illness</title>
            <para>[Begin History of Present Illness.]</para>
            <para>[Section Prompt: Prior Treatment.]</para>
            <para>[Section Selection Behavior: Select all that apply.]</para>
            <para>[Technical Note: Prior Treatment to be auto-populated when data is available.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; NS3 Protease Inhibitor plus Peginterferon
                            Alfa/Ribavirin</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; NS5A Protease Inhibitor</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Peginterferon Alfa/Ribavirin</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Simeprevir/Sofosbuvir</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Sofobuvir</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Sofobuvir/Ribavirin with or without Peginterferon
                            Alfa/Ribavirin</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Other medications or treatments<itemizedlist mark="none">
                                <listitem>
                                    <para>&lt;obtain&gt; Details and results of other medications or
                                        treatments</para>
                                </listitem>
                            </itemizedlist></para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Liver Complications or Extrahepatic Manifestations.]</para>
            <para>[Section Selection Behavior: Select all that apply.]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ascites due to live failure</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Cirrhosis</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Technical Note: If cirrhosis is selected, calculate Child Turcotte Pugh Class
                (CTP) automatically and pre-select A, B or C. Mechanism should be provided for the
                user to override the pre-selected class. Default is A. Class C requires at least one
                of the following: 1) total bilirubin > 3 mg/dL; or 2) serum albumin &lt; 2.8 g/dL;
                or 3) international normalized ratio > 2.30; or 4) moderate to severe ascites; or 5)
                grade III to IV or refractory hepatic encephalopathy. Class B does not have any of
                the criteria for class C and requires at least one of the following: 1) total
                bilirubin 2-3 mg/dL; or 2) serum albumin 2.8 to 3.5 g/dL; or 3) international
                normalized ratio 1.71 to 2.30; or 4) mild ascites; or 5) grade I to II
                encephalopathy or encephalopathy that is suppressed with medications. Class A
                requires all of the following: 1) total bilirubin &lt; 2 mg/dL; and 2) serum albumin
                > 3.5 g/dL; and 3) international normalized ratio =&lt;1.70; and 4) no ascites; and
                5) no encephalopathy. Provide link to
                https://www.hepatitisc.uw.edu/page/clinical-calculators/ctp]</para>
            <para>[Section Prompt: Child Turcotte Pugh Class for this patient.]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <itemizedlist mark="none">
                            <listitem>
                                <para>&#x2610; A</para>
                            </listitem>
                        </itemizedlist>
                    </listitem>
                </itemizedlist>
                <itemizedlist mark="none">
                    <listitem>
                        <itemizedlist mark="none">
                            <listitem>
                                <para>&#x2610; B</para>
                            </listitem>
                            <listitem>
                                <para>&#x2610; C</para>
                            </listitem>
                        </itemizedlist>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Technical Note: Encephalopathy should be automatically selected if data is
                available.]</para>
            <itemizedlist mark="none">
                <listitem>
                    <para>&#x2610; Encephalopathy </para>
                </listitem>
            </itemizedlist>
            <para>[Technical Note: Hepatocellular Carcinoma should be automatically selected if data
                is available.]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Hepatocellular Carcinoma </para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Liver Transplant<itemizedlist mark="none">
                                <listitem>
                                    <para>&lt;obtain&gt; Date</para>
                                </listitem>
                            </itemizedlist></para>
                        <para>&lt;obtain&gt; Hepatitis C Infection status of the allograft</para>
                    </listitem>
                </itemizedlist>
            </para>
            <itemizedlist mark="none">
                <listitem>
                    <para>&#x2610; Other Live Complications or Extrahepatic Manifestations <itemizedlist mark="none">
                            <listitem>
                                <para>&lt;obtain&gt; Details</para>
                            </listitem>
                        </itemizedlist></para>
                </listitem>
            </itemizedlist>
            <para>[End History of Present Illness.]</para>
        </section>
        <section>
            <title>Labs</title>
            <para>[Begin Labs.]</para>
            <para>[Technical Note: Please auto populate data in this section if it is
                available.]</para>
            <para>[Technical Note: If auto populated, please provide the most recent lab
                results.]</para>
            <para>[Technical Note: Please prompt provider to order a new Complete Blood Count if
                this there are no results or the date is not within 1 year.]</para>
            <para>[Section Prompt: Prior lab results:]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Complete Blood Count</para>
                    </listitem>
                </itemizedlist></para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&lt;obtain&gt; Date</para>
                        <para>Results<itemizedlist mark="none">
                                <listitem>
                                    <para>&lt;obtain&gt; White Blood Cell Count
                                        (K/microliter)</para>
                                </listitem>
                                <listitem>
                                    <para>&lt;obtain&gt; Mean Cell Volume (femtoliters) </para>
                                </listitem>
                                <listitem>
                                    <para>&lt;obtain&gt; Hemoglobin (g/dL)</para>
                                </listitem>
                                <listitem>
                                    <para>&lt;obtain&gt; Platelet Count (K/microliter)</para>
                                </listitem>
                            </itemizedlist></para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Technical Note: Please prompt provider to order a new Hepatic Function Panel if
                there are no results or the date is not within 1 year.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Hepatic Function Panel</para>
                    </listitem>
                </itemizedlist><itemizedlist mark="none">
                    <listitem>
                        <para>&lt;obtain&gt; Date</para>
                        <para>Results<itemizedlist mark="none">
                                <listitem>
                                    <para>&lt;obtain&gt; Albumin (d/dL)</para>
                                </listitem>
                                <listitem>
                                    <para>&lt;obtain&gt; Total Bilirubin (mg/dL)</para>
                                </listitem>
                                <listitem>
                                    <para>&lt;obtain&gt; Alanine Aminotransferase (U/L)</para>
                                </listitem>
                                <listitem>
                                    <para>&lt;obtain&gt; Aspartate Aminotransferase (U/L)</para>
                                </listitem>
                                <listitem>
                                    <para>&lt;obtain&gt; Alkaline Phosphatase (U/L)</para>
                                </listitem>
                            </itemizedlist></para>
                    </listitem>
                </itemizedlist></para>
            <para>[Technical Note: Please prompt provider to order a new International Normalized
                Ratio (INR) if this test has no results or the date is not within 1 year.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; International Normalized Ratio</para>
                    </listitem>
                </itemizedlist></para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <itemizedlist mark="none">
                            <listitem>
                                <para>&lt;obtain&gt; Date</para>
                                <para>&lt;obtain&gt; Results</para>
                            </listitem>
                        </itemizedlist>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Technical Note: Please prompt provider to order a new Glomerular Filtration Rate
                if there are no results or the date is not within 1 year.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Estimated Glomerular Filtration Rate</para>
                    </listitem>
                </itemizedlist><itemizedlist mark="none">
                    <listitem>
                        <itemizedlist mark="none">
                            <listitem>
                                <para>&lt;obtain&gt; Date</para>
                                <para>&lt;obtain&gt; Results (mL/min per 1.73 m^2)</para>
                            </listitem>
                        </itemizedlist>
                    </listitem>
                </itemizedlist></para>
            <para>[Technical Note: Please prompt provider to order a new Creatinine if there are no
                results or the date is not within 1 year.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Creatinine</para>
                    </listitem>
                </itemizedlist><itemizedlist mark="none">
                    <listitem>
                        <itemizedlist mark="none">
                            <listitem>
                                <para>&lt;obtain&gt; Date</para>
                                <para>&lt;obtain&gt; Results (mg/dL) </para>
                            </listitem>
                        </itemizedlist>
                    </listitem>
                </itemizedlist></para>
            <para>[Technical Note: Please prompt provider to order a new Hepatitis C Virus (HCV)
                Viral Load if there are no results or the date is not within 1 year.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; HCV Viral Load [Quantitative HCV Ribonucleic Acid
                            (RNA)]</para>
                    </listitem>
                </itemizedlist><itemizedlist mark="none">
                    <listitem>
                        <itemizedlist mark="none">
                            <listitem>
                                <para>&lt;obtain&gt; Date</para>
                                <para>&lt;obtain&gt; Results (IU/L)</para>
                            </listitem>
                        </itemizedlist>
                    </listitem>
                </itemizedlist></para>
            <para>[Technical Note: Please prompt provider to order a new HCV Genotype if there are
                no results.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; HCV Genotype</para>
                    </listitem>
                </itemizedlist></para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <itemizedlist mark="none">
                            <listitem>
                                <para>&lt;obtain&gt; Date</para>
                                <para>&lt;obtain&gt; Results</para>
                            </listitem>
                        </itemizedlist>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Technical Note: Please prompt provider to order a new Human Immunodeficiency
                Virus (HIV) test if there are no results or if the results are negative and the date
                is not within 5 years.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; HIV Test</para>
                    </listitem>
                </itemizedlist><itemizedlist mark="none">
                    <listitem>
                        <itemizedlist mark="none">
                            <listitem>
                                <para>&lt;obtain&gt; Date</para>
                                <para>&lt;obtain&gt; Results</para>
                            </listitem>
                        </itemizedlist>
                    </listitem>
                </itemizedlist></para>
            <para>[Technical Note: Please prompt provider to order a new Hepatitis B Screen if there
                are no results or the date is not within 10 years.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Hepatitis B Screen</para>
                    </listitem>
                </itemizedlist><itemizedlist mark="none">
                    <listitem>
                        <itemizedlist mark="none">
                            <listitem>
                                <para>&lt;obtain&gt; Date<itemizedlist mark="none">
                                        <listitem>
                                            <para> Results<itemizedlist mark="none">
                                                  <listitem>
                                                  <para>&lt;obtain&gt; HBsAg</para>
                                                  </listitem>
                                                  <listitem>
                                                  <para>&lt;obtain&gt; Anti-HBs</para>
                                                  </listitem>
                                                  <listitem>
                                                  <para>&lt;obtain&gt; Anti-HBc</para>
                                                  </listitem>
                                                </itemizedlist></para>
                                        </listitem>
                                    </itemizedlist></para>
                            </listitem>
                        </itemizedlist>
                    </listitem>
                </itemizedlist></para>
            <para>[End Labs.]</para>
        </section>
        <section>
            <title>Imaging</title>
            <para>[Begin Imaging.]</para>
            <para>[Technical Note: Corresponding links to the images should be attached
                automatically if text is provided for an interpretation field in this section. If no
                results are found, indicate this to the user.]</para>
            <para>&lt;obtain&gt; Liver Ultrasound Interpretation<itemizedlist mark="none">
                    <listitem>
                        <para>[Technical Note: Link to full Report and Images]</para>
                    </listitem>
                </itemizedlist></para>
            <para>&lt;obtain&gt; Liver Computed Tomography (CT) Interpretation<itemizedlist mark="none">
                    <listitem>
                        <para>[Technical Note: Link to full Report and Images]</para>
                    </listitem>
                </itemizedlist></para>
            <para>&lt;obtain&gt; Liver Magnetic Resonance Imaging (MRI) Interpretation<itemizedlist mark="none">
                    <listitem>
                        <para>[Technical Note: Link to full Report and Images]</para>
                    </listitem>
                </itemizedlist></para>
            <para>&lt;obtain&gt; Fibroscan Interpretation<itemizedlist mark="none">
                    <listitem>
                        <para>[Technical Note: Link to full Report and Images]</para>
                    </listitem>
                </itemizedlist></para>
            <para>[End Imaging.]</para>
            <para>[End Consult Request/Documentation Template.]</para>
        </section>
    </chapter>
    <chapter>
        <title>Order Set: Hepatitis C Elbasvir/Grazoprevir</title>
        <para>[Begin Order Set: Hepatitis C - Elbasvir/Grazoprevir.]</para>
        <section>
            <title>Knowledge Narrative</title>
            <para>[Begin Knowledge Narrative.]</para>
            <para>[See Clinical Context in Chapter 1.]</para>
            <para>[End Knowledge Narrative.]</para>
        </section>
        <section>
            <title>Medications</title>
            <para>[Begin Medications.]</para>
            <para>[Technical Note: This section should be available to any provider who is treating
                a patient with hepatitis C.]</para>
            <para>[Technical Note: Subsections in this section should be made available according to
                the subpopulation criteria identified in the subheadings, based on automated data
                evaluation and on data entered into the hepatitis C documentation template.]</para>
            <para>[Section Prompt: Elbasvir/grazoprevir is contraindicated in patients with
                decompensated cirrhosis.]</para>
            <para>[Section Prompt: Elbasvir/grazoprevir should not be used in combination with 1)
                strong CYP3A inducers; or 2) OATP1B1/3 inhibitors; or 3) efavirenz.]</para>
            <para>[Sectioin Prompt: Providers should check http://www.hep-druginteractions.org,
                https://www.hepatitis.va.gov/provider/guidelines/hcv-treatment-considerations.asp,
                and/or a pharmacist for additional drug interactions or contraindications before
                starting elbasvir/grazoprevir.]</para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1a,
                Treatment-Naïve or Treatment-Experienced (PEG/RBV), No NS5A Polymorphisms at
                Position 28, 30, 31, or 93, without Cirrhosis or with Compensated Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Elbasvir/grazoprevir (50 mg/100 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1a,
                Treatment-Naïve, with NS5A Polymorphisms at Position 28, 30, 31, or 93, without
                Cirrhosis or with Compensated Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Elbasvir/grazoprevir (50 mg/100 mg) 1 tablet oral, daily, 28
                            tablets 3 refills (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 2 capsules every morning
                            and 3 capsules every evening; take with food 140 capsules 2 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 3 capsules every morning
                            and 3 capsules every evening; take with food 168 capsules 2 refills
                            (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1a,
                Treatment-Experienced (First Generation Protease Inhibitor Plus PEG/RBV), No NS5A
                Polymorphisms at Position 28, 30, 31, or 93, without Cirrhosis or with Compensated
                Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Elbasvir/grazoprevir (50 mg/100 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)daily</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 2 capsules every morning
                            and 3 capsules every evening; take with food 140 capsules 2 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 3 capsules every morning
                            and 3 capsules every evening; take with food 168 capsules 2 refills
                            (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1a,
                Treatment-Experienced (PEG/RBV or First Generation Protease Inhibitor Plus PEG/RBV),
                with NS5A Polymorphisms at Position 28, 30, 31, or 93, without Cirrhosis or with
                Compensated Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Elbasvir/grazoprevir (50 mg/100 mg) 1 tablet oral, daily, 28
                            tablets 3 refills (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 2 capsules every morning
                            and 3 capsules every evening; take with food 140 capsules 3 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 3 capsules every morning
                            and 3 capsules every evening; take with food 168 capsules 3 refills
                            (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1b,
                Treatment-Naïve or Treatment-Experienced (PEG/RBV), without Cirrhosis or with
                Compensated Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Elbasvir/grazoprevir (50 mg/100 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1b,
                Treatment-Experienced (First Generation Protease Inhibitor Plus PEG/RBV), without
                Cirrhosis or with Compensated Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Elbasvir/grazoprevir (50 mg/100 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 2 capsules every morning
                            and 3 capsules every evening; take with food 140 capsules 2 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 3 capsules every morning
                            and 3 capsules every evening; take with food 168 capsules 2 refills
                            (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 4,
                Treatment-Naïve, without Cirrhosis or with Compensated Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Elbasvir/grazoprevir (50 mg/100 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 4,
                Treatment-Experienced (PEG/RBV), without Cirrhosis or with Compensated Cirrhosis
                (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Elbasvir/grazoprevir (50 mg/100 mg) 1 tablet oral, daily, 28
                            tablets 3 refills (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 2 capsules every morning
                            and 3 capsules every evening; take with food 140 capsules 3 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 3 capsules every morning
                            and 3 capsules every evening; take with food 168 capsules 3 refills
                            (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Reduced-Dose
                Ribavirin for Patients with Renal Impairment (Creatinine Clearance 30–50 mL/min/1.73 m^2).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 1 capsule every other
                            day, alternating with 2 capsules on alternate days; on 2-capsule days,
                            take 1 capsule in the morning and one capsule in the evening; take with
                            food 42 capsules 2 refills (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 1 capsule every other
                            day, alternating with 2 capsules on alternate days; on 2-capsule days,
                            take 1 capsule in the morning and one capsule in the evening; take with
                            food 42 capsules 3 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Reduced-Dose
                Ribavirin for Patients with Renal Impairment (Creatinine Clearance &lt; 30
                mL/min/1.73 m^2).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 1 capsule daily with food
                            28 capsules 2 refills (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 1 capsule daily with food
                            28 capsules 3 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[End Medications.]</para>
        </section>
        <section>
            <title>Laboratory Tests</title>
            <para>[Begin Laboratory Tests.]</para>
            <para>[Technical Note: This section should be available to users in gastroenterology
                settings and for primary care providers who are managing hepatitis C patients
                themselves or referring a patient to gastroenterology for management of hepatitis
                    C.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Complete blood count 1 time (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Hepatic function panel 1 time (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; International normalized ratio 1 time (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Basic metabolic panel 1 time (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Glomerular filtration rate 1 time (routine)</para>
                        <para>[Section Prompt: The following lab is recommended if not performed
                            within the previous 5 years.]<itemizedlist mark="none">
                                <listitem>
                                    <para>&#x2610; HCV genotype 1 time (routine)</para>
                                </listitem>
                            </itemizedlist></para>
                        <para>[Section Prompt: The following labs are recommended if not performed
                            within the previous 10 years.]<itemizedlist mark="none">
                                <listitem>
                                    <para>&#x2610; Hepatitis B surface antigen (HBsAg) 1 time
                                        (routine)</para>
                                </listitem>
                                <listitem>
                                    <para>&#x2610; Hepatitis B core antibody (HBcAb) 1 time
                                        (routine)</para>
                                </listitem>
                                <listitem>
                                    <para>&#x2610; Hepatitis B surface antibody (HBsAb) 1 time
                                        (routine)</para>
                                </listitem>
                                <listitem>
                                    <para>&#x2610; Hepatitis A antibody (HAVAb) 1 time
                                        (routine)</para>
                                </listitem>
                            </itemizedlist></para>
                        <para>[Section Prompt: The following lab is recommended if not performed
                            within the previous 6 months.]<itemizedlist mark="none">
                                <listitem>
                                    <para>&#x2610; HCV viral load (quantitative HCV RNA) 1 time
                                        (routine)</para>
                                </listitem>
                            </itemizedlist></para>
                        <para>[Section Prompt: The following lab is recommended if not performed
                            within the previous 5 years]<itemizedlist mark="none">
                                <listitem>
                                    <para>&#x2610; Resistance-associated substitutions 1 time
                                        (routine)</para>
                                </listitem>
                                <listitem>
                                    <para>&#x2610; HIV test 1 time (routine)</para>
                                </listitem>
                            </itemizedlist></para>
                    </listitem>
                </itemizedlist></para>
            <para>[Technical Note: The following order for qualitative human chorionic gonadotropin
                (HCG) should be available for female patients of reproductive age only.]</para>
            <para>[Section Prompt: The following lab is recommended if not performed within the
                previous 2 weeks.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Qualitative human chorionic gonadotropin 1 time
                            (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[End Laboratory Tests.]</para>
        </section>
        <section>
            <title>Patient and Caregiver Education</title>
            <para>[Begin Patient and Caregiver Education.]</para>
            <para>[Technical Note: This section should be available to users in gastroenterology
                settings and for primary care providers who are managing hepatitis C patients
                themselves or referring a patient to gastroenterology for management of hepatitis
                    C.]<itemizedlist mark="none">
                    <listitem>
                        <para>“Hepatitis C Information for Veterans” available at
                            https://www.hepatitis.va.gov/pdf/Hepatitis-C-Factsheet-Veterans.pdf
                        </para>
                    </listitem>
                    <listitem>
                        <para>“Chronic Hepatitis C and Alcohol Use” available at
                            https://www.hepatitis.va.gov/products/patient/hepatitisC-alcohol-brochure.asp
                        </para>
                    </listitem>
                    <listitem>
                        <para>“What to Expect Before Your Treatment for Hepatitis C Virus” available
                            at
                            https://www.hepatitis.va.gov/products/patient/hepatitisC-pretreatment.asp
                        </para>
                    </listitem>
                    <listitem>
                        <para> “Ribavirin: Information for Patients” available at
                            https://www.hepatitis.va.gov/pdf/patient-ribavirin.pdf </para>
                    </listitem>
                    <listitem>
                        <para>“Taking Your Hepatitis C Therapy: Zepatier(TM) with or without
                            Ribavirin” available at
                            https://www.hepatitis.va.gov/pdf/patient-zepatier.pdf</para>
                    </listitem>
                    <listitem>
                        <para>“Managing Side Effects of Zepatier(TM)” available at
                            https://www.hepatitis.va.gov/pdf/side-effects-zepatier.pdf </para>
                    </listitem>
                    <listitem>
                        <para>“Managing Side Effects of Zepatier(TM) + Ribavirin” available at
                            https://www.hepatitis.va.gov/pdf/side-effects-zepatier-ribavirin.pdf
                        </para>
                    </listitem>
                    <listitem>
                        <para>“Tracking My Hepatitis C Treatment Results” available at
                            https://www.hepatitis.va.gov/products/patient/tracking-chart.asp </para>
                    </listitem>
                </itemizedlist></para>
            <para>[End Patient and Caregiver Education.]</para>
            <para>[End Order Set: Hepatitis C - Elbasvir/Grazoprevir.]</para>
        </section>
    </chapter>
    <chapter>
        <title>Order Set: Hepatitis C Ledipasvir/Sofobuvir</title>
        <para>[Begin Order Set: Hepatitis C - Ledipasvir/Sofosbuvir.]</para>
        <section>
            <title>Knowledge Narrative</title>
            <para>[Begin Knowledge Narrative.]</para>
            <para>[See Clinical Context in Chapter 1.]</para>
            <para>[End Knowledge Narrative.]</para>
        </section>
        <section>
            <title>Medications</title>
            <para>[Begin Medications.]</para>
            <para>[Technical Note: This section should be available to any provider who is treating
                a patient with hepatitis C.]</para>
            <para>[Technical Note: Subsections in this section should be made available according to
                the subpopulation criteria identified in the subheadings, based on data pulled
                automatically or entered into the hepatitis C documentation template.]</para>
            <para>[Section Prompt: Ledipasvir/sofosbuvir should not be used in patients with severe
                renal impairment (eGFR&lt;30mL/min/1.73 m^2), with end-stage-renal disease, or on
                hemodialysis.]</para>
            <para>[Section Prompt: Ledipasvir/sofosbuvir should not be used in combination with
                amiodarone, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin,
                rifampin, rifapentine, rosuvastatin, St. John’s wort,
                elvitegravir/cobicistat/emtricitabine/tenofovir, tipranavir/ritonavir, or
                simeprevir.]</para>
            <para>[Section Prompt: Ledipasvir/sofosbuvir should not be used in patients who require
                twice-daily proton pump inhibitor therapy for esophageal disease.]</para>
            <para>[Section Prompt: Providers should check http://www.hep-druginteractions.org,
                https://www.hepatitis.va.gov/provider/guidelines/hcv-treatment-considerations.asp,
                and/or a pharmacist for additional drug interactions or contraindications before
                starting ledipasvir/sofosbuvir.]</para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                Treatment-Naïve, without Cirrhosis, HCV RNA &lt; 6 Million IU/mL.]</para>
            <para>[Section Prompt: An 8-week duration of therapy should be used in non–African
                American patients only; a 12-week duration of therapy should be used in patients who
                are African American.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 1 refill (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Technical Note: The following order should be available for patients who are
                African American.]</para>
            <para>[Section Prompt: For patients who are African American:]</para>
            <para>
                <itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist>
            </para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                Treatment-Naïve, without Cirrhosis, HCV RNA >= 6 Million IU/mL.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                Treatment-Naïve, without Cirrhosis, with HIV Coinfection.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                Treatment-Naïve, with Compensated Cirrhosis.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                Treatment-Experienced (PEG-RBV with or without Protease Inhibitor), without Cirrhosis.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                Treatment-Experienced (PEG-RBV with or without Protease Inhibitor), with Compensated
                Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 2 capsules every morning
                            and 3 capsules every evening; take with food 140 capsules 2 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 3 capsules every morning
                            and 3 capsules every evening; take with food 168 capsules 2 refills
                            (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                Treatment-Experienced (PEG-RBV with or without Protease Inhibitor), Ribavirin
                Intolerant, with Compensated Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 5 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1
                with Decompensated Cirrhosis (CTP B or C).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 1 capsule every morning
                            and 2 capsules every evening; take with food; increase dose by 1 capsule
                            every 2 weeks, up to 5 pills per day as tolerated 126 capsules 2 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 1 capsule every morning
                            and 2 capsules every evening; take with food; increase dose by 1 capsule
                            every 2 weeks, up to 6 pills per day as tolerated 140 capsules 2 refills
                            (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                Ribavirin Intolerant, with Decompensated Cirrhosis (CTP B or C).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 5 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                Pre- or Post-Liver Transplant (Including CTP A, B, or C or Suitable Candidate with
                Hepatocellular Carcinoma).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 1 capsule every morning
                            and 2 capsules every evening; take with food; increase dose by 1 capsule
                            every 2 weeks, up to 5 pills per day as tolerated 126 capsules 2 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 1 capsule every morning
                            and 2 capsules every evening; take with food; increase dose by 1 capsule
                            every 2 weeks, up to 6 pills per day as tolerated 140 capsules 2 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 2 capsules every morning
                            and 3 capsules every evening; take with food 140 capsules 2 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 3 capsules every morning
                            and 3 capsules every evening; take with food 168 capsules 2 refills
                            (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 4,
                5, or 6 without Cirrhosis or with Compensated Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 4,
                5, or 6 with Decompensated Cirrhosis (CTP B or C).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 1 capsule every morning
                            and 2 capsules every evening; take with food; increase dose by 1 capsule
                            every 2 weeks, up to 5 pills per day as tolerated 126 capsules 2 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 1 capsule every morning
                            and 2 capsules every evening; take with food; increase dose by 1 capsule
                            every 2 weeks, up to 6 pills per day as tolerated 140 capsules 2 refills
                            (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 4,
                Post-Liver Transplant.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ledipasvir/sofosbuvir (90 mg/400 mg) 1 tablet oral, daily, 28
                            tablets 2 refills (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 1 capsule every morning
                            and 2 capsules every evening; take with food; increase dose by 1 capsule
                            every 2 weeks, up to 5 pills per day as tolerated 126 capsules 2 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 1 capsule every morning
                            and 2 capsules every evening; take with food; increase dose by 1 capsule
                            every 2 weeks, up to 6 pills per day as tolerated 140 capsules 2 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 2 capsules every morning
                            and 3 capsules every evening; take with food 140 capsules 2 refills
                            (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 3 capsules every morning
                            and 3 capsules every evening; take with food 168 capsules 2 refills
                            (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Reduced-Dose
                Ribavirin for Patients with Renal Impairment (Creatinine Clearance 30–50 mL/min/1.73 m^2).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Ribavirin 200 mg capsule oral, take 1 capsule every other
                            day, alternating with 2 capsules on alternate days; on 2-capsule days,
                            take 1 capsule in the morning and one capsule in the evening; take with
                            food 42 capsules 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[End Medications.]</para>
        </section>
        <section>
            <title>Laboratory Tests</title>
            <para>[Begin Laboratory Tests.]</para>
            <para>[Technical Note: This section should be available to users in gastroenterology
                settings and for primary care providers who are managing hepatitis C patients
                themselves or referring a patient to gastroenterology for management of hepatitis
                    C.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Complete blood count 1 time (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Hepatic function panel 1 time (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; International normalized ratio 1 time (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Basic metabolic panel 1 time (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Glomerular Filtration rate 1 time (routine)</para>
                        <para>[Section Prompt: The following lab is recommended if not performed
                            within the previous 5 years.]</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; HCV genotype 1 time (routine)</para>
                        <para>[Section Prompt: The following labs are recommended if not performed
                            within the previous 10 years.]<itemizedlist mark="none">
                                <listitem>
                                    <para>&#x2610; Hepatitis B surface antigen (HBsAg) 1 time
                                        (routine)</para>
                                </listitem>
                                <listitem>
                                    <para>&#x2610; Hepatitis B core antibody (HBcAb) 1 time
                                        (routine)</para>
                                </listitem>
                                <listitem>
                                    <para>&#x2610; Hepatitis B surface antibody (HBsAb) 1 time
                                        (routine)</para>
                                </listitem>
                                <listitem>
                                    <para>&#x2610; Hepatitis A antibody (HAVAb) 1 time
                                        (routine)</para>
                                </listitem>
                            </itemizedlist></para>
                        <para>[Section Prompt: The following lab is recommended if not performed
                            within the previous 6 months.]</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; HCV viral load (quantitative HCV RNA) 1 time (routine)</para>
                        <para>[Section Prompt: The following lab is recommended if not performed
                            within the previous 5 years.]</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; HIV test 1 time (routine)</para>
                        <para>[Technical Note: The following order for qualitative human chorionic
                            gonadotropin (HCG) should not be available for female patients of
                            reproductive age only.]</para>
                        <para>[Section Prompt: The following lab is recommended if not performed
                            within the previous 2 weeks.]</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Qualitative human chorionic gonadotropin 1 time
                            (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[End Laboratory Tests.]</para>
        </section>
        <section>
            <title>Patient and Caregiver Education</title>
            <para>[Begin Patient and Caregiver Education.]</para>
            <para>[This section should be available to users in gastroenterology settings and for
                primary care providers who are managing hepatitis C patients themselves or referring
                a patient to gastroenterology for management of hepatitis C.]<itemizedlist
                    mark="none">
                    <listitem>
                        <para>“Hepatitis C Information for Veterans” available at
                            https://www.hepatitis.va.gov/pdf/Hepatitis-C-Factsheet-Veterans.pdf
                        </para>
                    </listitem>
                    <listitem>
                        <para>“Chronic Hepatitis C and Alcohol Use” available at
                            https://www.hepatitis.va.gov/products/patient/hepatitisC-alcohol-brochure.asp
                        </para>
                    </listitem>
                    <listitem>
                        <para>“What to Expect Before Your Treatment for Hepatitis C Virus” available
                            at
                            https://www.hepatitis.va.gov/products/patient/hepatitisC-pretreatment.asp
                        </para>
                    </listitem>
                    <listitem>
                        <para>“Ribavirin: Information for Patients” available at
                            https://www.hepatitis.va.gov/pdf/patient-ribavirin.pdf </para>
                    </listitem>
                    <listitem>
                        <para>“Taking Your Hepatitis C Therapy: Harvoni(R) with or without
                            Ribavirin” available at
                            https://www.hepatitis.va.gov/pdf/patient-harvoni.pdf </para>
                    </listitem>
                    <listitem>
                        <para>“Managing Side Effects of Harvoni(R)” available at
                            https://www.hepatitis.va.gov/products/patient/side-effects-handouts.asp
                        </para>
                    </listitem>
                    <listitem>
                        <para>“Managing Side Effects of Harvoni(R) and Ribavirin” available at
                            https://www.hepatitis.va.gov/pdf/side-effects-harvoni-ribavirin.pdf</para>
                    </listitem>
                    <listitem>
                        <para>“Tracking My Hepatitis C Treatment Results” available at
                            https://www.hepatitis.va.gov/products/patient/tracking-chart.asp </para>
                    </listitem>
                </itemizedlist></para>
            <para>[End Patient and Caregiver Education.]</para>
            <para>[End Order Set: Hepatitis C - Ledispasvir/Sofosbuvir.]</para>
        </section>
    </chapter>
    <chapter>
        <title>Order Set: Hepatitis C Glecaprevir/Pibrentasvir</title>
        <para>[Begin Order Set: Hepatitis C - Glecaprevir/Pibrentavir.]</para>
        <section>
            <title>Knowledge Narrative</title>
            <para>[Begin Knowledge Narrative.]</para>
            <para>[See Clinical Context in Chapter 1.]</para>
            <para>[End Knowledge Narrative.]</para>
        </section>
        <section>
            <title>Medications</title>
            <para>[Begin Medications.]</para>
            <para>[Technical Note: This section should be available to any provider who is treating
                a patient with hepatitis C.]</para>
            <para>[Technical Note: Subsections in this section should be made available according to
                the subpopulation criteria identified in the subheadings, based on data pulled
                automatically or on data that is entered into the hepatitis C documentation
                template.]</para>
            <para>[Section Prompt: Glecaprevir/pibrentasvir should not be used in patients with
                decompensated cirrhosis (CTP B or C).]</para>
            <para>[Section Prompt: Glecaprevir/pibrentasvir should not be used in combination with
                atazanavir or rifampin.]</para>
            <para>[Section Prompt: Providers should check http://www.hep-druginteractions.org,
                https://www.hepatitis.va.gov/provider/guidelines/hcv-treatment-considerations.asp,
                and/or a pharmacist for additional drug interactions or contraindications before
                starting glecaprevir/pibrentasvir.]</para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                2, 3, 4, 5, or 6, Treatment-Naïve, without Cirrhosis.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral,
                            daily, 84 tablets 1 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                2, 3, 4, 5, or 6, Treatment-Naïve, with Compensated Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral,
                            daily, 84 tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                Treatment-Experienced (NS5A Protease Inhibitor without Prior NS3/4A Protease
                Inhibitor), without Cirrhosis.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral,
                            daily, 84 tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                2, 4, 5, or 6, Treatment-Experienced (Interferon, Pegylated Interferon, Ribavirin,
                and/or Sofosbuvir), without Cirrhosis.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral,
                            daily, 84 tablets 1 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 3,
                Treatment-Experienced (Interferon, Pegylated Interferon, Ribavirin, and/or
                Sofosbuvir), without Cirrhosis.]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral,
                            daily, 84 tablets 3 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                Treatment-Experienced (NS5A Protease Inhibitor without Prior NS3/4A Protease
                Inhibitor), with Compensated Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral,
                            daily, 84 tablets 3 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                Treatment-Experienced (NS3/4A Protease Inhibitor without Prior NS5A Protease
                Inhibitor), with Compensated Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral,
                            daily, 84 tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 1,
                2, 4, 5, or 6, Treatment-Experienced (Interferon, Pegylated Interferon, Ribavirin,
                and/or Sofosbuvir), with Compensated Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral,
                            daily, 84 tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[Section Prompt: Qualifications for the following treatment include: Genotype 3,
                Treatment-Experienced (Interferon, Pegylated Interferon, Ribavirin, and/or
                Sofosbuvir), with Compensated Cirrhosis (CTP A).]<itemizedlist mark="none">
                    <listitem>
                        <para>&#x2610; Glecaprevir/pibrentasvir (100 mg/40 mg) 3 tablets oral,
                            daily, 84 tablets 2 refills (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[End Medications.]</para>
        </section>
        <section>
            <title>Laboratory Tests</title>
            <para>[Begin Laboratory Tests.]</para>
            <para>[Technical Note: This section should be available to users in gastroenterology
                settings and for primary care providers managing hepatitis C patients themselves or
                referring a patient to gastroenterology for management of hepatitis C.]<itemizedlist
                    mark="none">
                    <listitem>
                        <para>&#x2610; Complete blood count 1 time (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Hepatic function panel 1 time (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; International normalized ratio 1 time (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Basic metabolic panel 1 time (routine)</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Glomerular filtration rate 1 time (routine)</para>
                        <para>[Section Prompt: The following lab is recommended if not performed
                            within the previous 5 years.]</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; HCV genotype 1 time (routine)</para>
                        <para>[Section Prompt: The following labs are recommended if not performed
                            within the previous 10 years.]<itemizedlist mark="none">
                                <listitem>
                                    <para>&#x2610; Hepatitis B surface antigen (HBsAg) 1 time
                                        (routine)</para>
                                </listitem>
                                <listitem>
                                    <para>&#x2610; Hepatitis B core antibody (HBcAB) 1 time
                                        (routine)</para>
                                </listitem>
                                <listitem>
                                    <para>&#x2610; Hepatitis B surface antibody (HBsAb) 1 time
                                        (routine)</para>
                                </listitem>
                                <listitem>
                                    <para>&#x2610; Hepatitis A antibody (HAVAb) 1 time
                                        (routine)</para>
                                </listitem>
                            </itemizedlist></para>
                        <para>[Section Prompt: The following lab is recommended if not performed
                            within the previous 6 months.]<itemizedlist mark="none">
                                <listitem>
                                    <para>&#x2610; HCV viral load (quantitative HCV RNA) 1 time
                                        (routine)</para>
                                </listitem>
                                <listitem>
                                    <para>&#x2610; HIV test 1 time (routine)</para>
                                </listitem>
                            </itemizedlist></para>
                        <para>[Technical Note: The following order for qualitative human chorionic
                            gonadotropin (HCG) should be available for female patients of
                            reproductive age only.]</para>
                        <para>[Section Prompt: The following lab is recommended if not performed
                            within the previous 2 weeks.]</para>
                    </listitem>
                    <listitem>
                        <para>&#x2610; Qualitative human chorionic gonadotropin 1 time
                            (routine)</para>
                    </listitem>
                </itemizedlist></para>
            <para>[End Laboratory Tests.]</para>
        </section>
        <section>
            <title>Patient and Caregiver Education</title>
            <para>[Begin Patient and Caregiver Education.]</para>
            <para>[This section should be available to users in gastroenterology settings and for
                primary care providers who are managing hepatitis C patients themselves or referring
                a patient to gastroenterology for management of hepatitis C.]<itemizedlist
                    mark="none">
                    <listitem>
                        <para>“Hepatitis C Information for Veterans” available at
                            https://www.hepatitis.va.gov/pdf/Hepatitis-C-Factsheet-Veterans.pdf
                        </para>
                    </listitem>
                    <listitem>
                        <para>“Chronic Hepatitis C and Alcohol Use” available at
                            https://www.hepatitis.va.gov/products/patient/hepatitisC-alcohol-brochure.asp
                        </para>
                    </listitem>
                    <listitem>
                        <para>“What to Expect Before Your Treatment for Hepatitis C Virus” available
                            at
                            https://www.hepatitis.va.gov/products/patient/hepatitisC-pretreatment.asp
                        </para>
                    </listitem>
                    <listitem>
                        <para>“Taking Your Hepatitis C Therapy: Mavyret(TM)” available at
                            https://www.hepatitis.va.gov/pdf/patient-mavyret.pdf</para>
                    </listitem>
                    <listitem>
                        <para>“Managing Side Effects of Mavyret(TM)” available at
                            https://www.hepatitis.va.gov/pdf/side-effects-mavyret.pdf</para>
                    </listitem>
                    <listitem>
                        <para>“Tracking My Hepatitis C Treatment Results” available at
                            https://www.hepatitis.va.gov/products/patient/tracking-chart.asp </para>
                    </listitem>
                </itemizedlist></para>
            <para>[End Patient and Caregiver Education.]</para>
            <para>[End Order Set: Hepatitis C - Glecaprevir/Pibrentavir.]</para>
        </section>
    </chapter>
    <bibliography>
        <title>Bibliography/Evidence</title>
        <biblioentry>
            <author>
                <orgname>American Association for the Study of Liver Diseases and the Infectious
                    Diseases Society of America</orgname>
            </author>
            <citetitle pubwork="webpage">HCV Guidance: Recommendations for Testing, Managing, and
                Treating Hepatitis C</citetitle>
            <bibliomisc><link xlink:href="http://www.hcvguidelines.org/"/></bibliomisc>
            <pubdate>Updated September 2017</pubdate>
        </biblioentry>
        <biblioentry>
            <author>
                <personname><surname>Fox</surname><firstname>RK</firstname></personname>
            </author>
            <citetitle pubwork="webpage">Summary of FDA Approval for Mavyret</citetitle>
            <bibliomisc><link
                    xlink:href="https://www.hepatitis.va.gov/provider/hcv/mavyret-approval.asp"
                /></bibliomisc>
            <pubdate>Published August 2017</pubdate>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. Department of Veterans Affairs</orgname>
            </author>
            <citetitle pubwork="webpage">After the Initial Diagnosis of HCV: Overview of Next
                Steps</citetitle>
            <bibliomisc><link xlink:href="https://www.hepatitis.va.gov/products/next-steps.asp"
                /></bibliomisc>
            <pubdate>Published May 2017</pubdate>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. Department of Veterans Affairs National Hepatitis C Resource Center
                    Program and the National Viral Hepatitis Program</orgname>
            </author>
            <citetitle pubwork="webpage">Chronic Hepatitis C Virus (HCV) Infection: Treatment
                Considerations from the Department of Veterans Affairs National Hepatitis C Resource
                Center Program and the HIV, Hepatitis, and Related Conditions Program in the Office
                of Specialty Care Services</citetitle>
            <bibliomisc><link
                    xlink:href="https://www.hepatitis.va.gov/provider/guidelines/hcv-treatment-considerations.asp"
                /></bibliomisc>
            <pubdate>Updated March 2017</pubdate>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine</orgname>
            </author>
            <citetitle pubwork="webpage">HARVONI- ledipasvir and sofosbuvir tablet, film coated
                [Gilead Sciences, Inc]</citetitle>
            <bibliomisc><link
                    xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4ec77e4-bae8-4db0-b3d5-bde09c5fa075"
                /></bibliomisc>
            <pubdate>Updated April 2017</pubdate>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine</orgname>
            </author>
            <citetitle pubwork="webpage">MAVYRET- glecaprevir and pibrentasvir tablet, film coated
                [AbbVie Inc.]</citetitle>
            <bibliomisc><link
                    xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7bf99777-0401-9095-8645-16c6e907fcc0"
                /></bibliomisc>
            <pubdate>Updated August 2017</pubdate>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine</orgname>
            </author>
            <citetitle pubwork="webpage">REBETOL- ribavirin capsule; REBETOL- ribavirin liquid
                [Merck Sharp &amp; Dohme Corp.]</citetitle>
            <bibliomisc><link
                    xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04d2b6f4-bd9b-4871-9527-92c81aa2d4d0"
                /></bibliomisc>
            <pubdate>Updated January 2016</pubdate>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>U.S. National Library of Medicine</orgname>
            </author>
            <citetitle pubwork="webpage">ZEPATIER- elbasvir and grazoprevir tablet, film coated
                [Merck Sharp &amp; Dohme Corp.]</citetitle>
            <bibliomisc><link
                    xlink:href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=164dc02a-9180-426a-b8b5-04ab39d2bbd4"
                /></bibliomisc>
            <pubdate>Updated February 2017</pubdate>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>VA Pharmacy Benefits Management Services, Medical Advisory Panel, VISN
                    Pharmacist Executives and Office of Public Health</orgname>
            </author>
            <citetitle pubwork="webpage">Elbasvir/Grazoprevir (ZepatierTM) Criteria for
                Use</citetitle>
            <bibliomisc><link xlink:href="https://www.pbm.va.gov/apps/VANationalFormulary/"
                /></bibliomisc>
            <pubdate>Published February 2016</pubdate>
        </biblioentry>
        <biblioentry>
            <author>
                <orgname>VA Pharmacy Benefits Management Services, Medical Advisory Panel, VISN
                    Pharmacist Executives and Office of Public Health</orgname>
            </author>
            <citetitle pubwork="webpage">Ledipasvir/Sofosbuvir (Harvoni®) and Sofosbuvir/Velpatasvir
                (Epclusa®) Criteria for Use</citetitle>
            <bibliomisc><link xlink:href="https://www.pbm.va.gov/apps/VANationalFormulary/"
                /></bibliomisc>
            <pubdate>Published September 2016</pubdate>
        </biblioentry>
    </bibliography>
    <appendix>
        <title>Existing Sample VA Artifacts</title>
        <para>Figures A.1 through A.8 for the Hepatitis C - Elbasvir/Grazoprevir - Order Set are
            from the Portland VAMC.</para>
        <figure>
            <title>Hepatitis C Treatment</title>
            <mediaobject>
                <alt>Screenshot of Prescribers for Hepatitis C Treatment stating that the following
                    information is needed to complete the request for sofosbuvir in compliance with
                    VISN 20 formulary guidelines.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig1HepatitisCTreatment.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Template: Formulary Exception- Hepatitis C Virus (HCV) Output Phenolic
                Acid-responsive Transcriptional Regulator (PADR) (Image 1 of 5)</title>
            <mediaobject>
                <alt>Screenshot of a Template for Formulary Exception- HCV Output PADR that contains
                    check boxes for the HCV treatment and regimens to be requested.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig2HCVTreatment.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Template: Formulary Exception- Hepatitis C Virus (HCV) Output Phenolic
                Acid-responsive Transcriptional Regulator (PADR) (Image 2 of 5)</title>
            <mediaobject>
                <alt>Screenshot of a continuation of a Template for Formulary Exception- HCV Output
                    PADR that includes check boxes for expected duration of treatments (in number of
                    weeks) and Labs.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig3HCVTreatment.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Template: Formulary Exception- Hepatitis C Virus (HCV) Output Phenolic
                Acid-responsive Transcriptional Regulator (PADR) (Image 3 of 5)</title>
            <mediaobject>
                <alt>Screenshot of the Template for Formulary Exception- HCV Output PADR filled out
                    to include the start of HCV Treatment, Experienced Treatment History, Resistance
                    Testing, and a positive for cirrhotic.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig4HCVTreatmentFilledOut.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Template: Formulary Exception- Hepatitis C Virus (HCV) Output Phenolic
                Acid-responsive Transcriptional Regulator (PADR) (Image 4 of 5)</title>
            <mediaobject>
                <alt>Screenshot of the Template for Formulary Exception- HCV Output PADR filled out
                    to include the Child Pugh Scoring Tool and showing that the patient has CKD as a
                    special condition.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig5HCVTreatmentChildPughScoringTool.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Template: Formulary Exception- Hepatitis C Virus (HCV) Output Phenolic
                Acid-responsive Transcriptional Regulator (PADR) (Image 5 of 5)</title>
            <mediaobject>
                <alt>Screenshot of the Template for Formulary Exception- HCV Output PADR filled out
                    to include that Ribavirin is needed.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig6HCVTreatmentRibavirin.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Fibrosis- 4 (FIB-4) Calculator (Image 1 of 2)</title>
            <mediaobject>
                <alt>Screenshot from Hepatitis C Online describing that the Fibrosis- 4 score helps
                    to estimate the amount of scarring in the liver. Enter the required values to
                    calculate the FIB-4 value. It will appear in the oval on the far right.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig7FIB-4Calculator.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Fibrosis- 4 (FIB-4) Calculator (Image 2 of 2)</title>
            <mediaobject>
                <alt>Screenshot from Hepatitis C Online continuing the information about the
                    Fibrosis- 4 (FIB-4) Calculator.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig8FIB-4Calculator.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <para>Figures A.9 through A.11 for the Hepatitis C - Ledipasvir/Sofosbuvir - Order Set are
            from the Portland VAMC.</para>
        <figure>
            <title>Template: Hepatitis C Virus (HCV) Output Phenolic Acid-responsive Transcriptional
                Regulator (PADR) (Image 1 of 3)</title>
            <mediaobject>
                <alt>Screenshot of the Template for Formulary Exception- HCV Output PADR filled out
                    to include the start of HCV Treatment, Experienced Treatment History, Resistance
                    Testing, and a positive for cirrhotic.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig9StartofHCVTreatment.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Template: Hepatitis C Virus (HCV) Output Phenolic Acid-responsive Transcriptional
                Regulator (PADR) (Image 2 of 3)</title>
            <mediaobject>
                <alt>Screenshot of the Template for Formulary Exception- HCV Output PADR filled out
                    to include the Child Pugh Scoring Tool and showing that the patient has HIV,
                    Liver Transplant, and CKD as special conditions.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig10SpecialConditions.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Template: Hepatitis C Virus (HCV) Output Phenolic Acid-responsive Transcriptional
                Regulator (PADR) (Image 3 of 3)</title>
            <mediaobject>
                <alt>Screenshot of the Template for Formulary Exception- HCV Output PADR filled out
                    to include the HCV Regimen Requested is Viekira and that Ribavirin is
                    needed.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig11HCVRegimenRequested.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <para>Tables A.1 through A.10 are from the Portland VAMC.</para>
        <para>Patients Without Cirrhosis:</para>
        <table>
            <title>Genotype 1</title>
            <tgroup cols="5">
                <tbody>
                    <row>
                        <entry><emphasis role="bold">Treatment History</emphasis></entry>
                        <entry><emphasis role="bold">Baseline Viral Load</emphasis></entry>
                        <entry><emphasis role="bold">Preferred Regimen (Cost)</emphasis></entry>
                        <entry><emphasis role="bold">Alternative Regimen(s)
                            (Cost)</emphasis></entry>
                        <entry><emphasis role="bold">Comments</emphasis></entry>
                    </row>
                    <row>
                        <entry>Treatment naive</entry>
                        <entry>
                            <para>&lt;6 million IU/mL (Including HCV/HIV coinfection) </para> 
                            <para>>6 million IU/mL</para>
                        </entry>
                        <entry>
                            <para>Harvoni x 8 weeks
                                ($10,446)
                                (Not African American)
                            </para>
                            <para>Genotype 1a: Harvoni x 12 weeks ($15,669) Genotype 1b: Zepatier x
                                12 weeks ($15,522) </para>
                        </entry>
                        <entry>Genotype 1a:
                            Zepatier  x12 weeks in patients without baseline NS5A RAV
                            ($15,522)
                            Zepatier + Ribavirin x 16 weeks in patients with baseline NS5A RAV
                            ($20,892)
                            
                            Genotype 1b:
                            Harvoni x 12 weeks
                            ($15,669)
                        </entry>
                        <entry>Consider Zepatier for patients who are not candidates for Harvoni:
                            -CrCl &lt;30ml/min -Drug interactions (amiodarone) -Patients who are on
                            high dose PPI and cannot hold PPI while on treatment</entry>
                    </row>
                    <row>
                        <entry>Treatment Experienced INF/RBV</entry>
                        <entry>N/A</entry>
                        <entry>Genotype 1a:
                            Harvoni x 12 weeks
                            ($15,669)
                            *May consider ribavirin
                            (-) RBV: 33/35 (94%)
                            (+) RBV: 38/38 (100%)
                            
                            Genotype 1b:
                            Zepatier x 12 weeks
                            ($15,522)
                        </entry>
                        <entry>Genotype 1a:
                            Zepatier  x12 weeks in patients without baseline NS5A RAV
                            ($15,522)
                            Zepatier + Ribavirin x 16 weeks in patients with baseline NS5A RAV
                            ($20,892)
                            
                            Genotype 1b:
                            Harvoni x 12 weeks
                            ($15,522)
                        </entry>
                        <entry></entry>
                    </row>
                    <row>
                        <entry>Treatment Experienced PI/INF/RBV</entry>
                        <entry>N/A</entry>
                        <entry>Genotype 1a:
                            Harvoni x 12 weeks
                            ($15,669)
                            *May consider ribavirin
                            (-) RBV: 50/52 (96%)
                            (+) RBV: 51/51 (100%)
                            
                            Genotype 1b:
                            Harvoni x 12 weeks
                            ($15,669)
                            *May consider ribavirin
                        </entry>
                        <entry>Genotype 1a:
                            Zepatier + Ribavirin x12 weeks in patients without baseline NS5A RAV
                            ($15,522)
                            Zepatier + Ribavirin x 16 weeks in patients with baseline NS5A RAV
                            ($20,892)
                            
                            Genotype 1b:
                            Zepatier + Ribavirin x 12 weeks
                            ($15,522)
                        </entry>
                        <entry></entry>
                    </row>
                    <row>
                        <entry>DAA Treatment Experienced *Non NS5A*</entry>
                        <entry>N/A</entry>
                        <entry>Harvoni + RBV x 12 weeks
                            ($15,669)
                            
                            Epclusa +/- RBV x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Harvoni x 24 weeks
                            ($31,338)
                        </entry>
                        <entry>Likely will not need resistance testing</entry>
                    </row>
                    <row>
                        <entry>DAA Treatment Experienced *NS5A*</entry>
                        <entry>N/A</entry>
                        <entry>Zepatier + Sofosbuvir + RBV x 12 to 16 weeks (Consider 16 weeks for Y93 mutation)
                            
                            Epclusa + RBV x 24 weeks (if strong NS5A mutation is present)
                            ($90,000)
                        </entry>
                        <entry>Harvoni + RBV x 12 weeks
                            (If no NS5A mutation)
                            
                            Harvoni x 24 weeks (if no NS5A mutation)
                            ($31,338)
                            
                            Epclusa +/- RBV x 12 weeks (If no or weak NS5A mutation)
                        </entry>
                        <entry>Obtain resistance testing (NS5A +/- PI)
                            Consider waiting for future options if no urgency to treat
                            Treatment option depends on duration of previous treatment, presence of NS5A RAS, and what kind of NS5A RAS
                        </entry>
                    </row>
                    <row>
                        <entry>CrCl &lt;30mL/min or ESRD</entry>
                        <entry>N/A</entry>
                        <entry>Genotype 1a:
                            Zepatier x 12 weeks in patients without baseline NS5A RAV, 16 weeks with RAV
                            ($15,522)
                            
                            Genotype 1b:
                            Zepatier x 12 weeks
                            ($15,522)
                        </entry>
                        <entry>Genotype 1a:
                            Viekira Pack  + Low Dose RBV x 12 weeks
                            ($15,522.36)
                            
                            Genotype 1b:
                            Viekira Pack x 12 weeks
                            ($15,522.36)
                        </entry>
                        <entry>RBV 200mg daily if used in CKD/ESRD patients</entry>
                    </row>
                </tbody>
            </tgroup>
        </table>
        <table>
            <title>Genotype 2</title>
            <tgroup cols="4">
                <tbody>
                    <row>
                        <entry><emphasis role="bold">Treatment History</emphasis></entry>
                        <entry><emphasis role="bold">Preferred Regimen (Cost)</emphasis></entry>
                        <entry><emphasis role="bold">Alternative Regimen(s)</emphasis></entry>
                        <entry><emphasis role="bold">Comments</emphasis></entry>
                    </row>
                    <row>
                        <entry>Naïve</entry>
                        <entry>Epclusa x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Harvoni + Ribavirin x 12 weeks
                            ($15,669)
                        </entry>
                        <entry></entry>
                    </row>
                    <row>
                        <entry>Treatment Experienced INF/RBV</entry>
                        <entry>Epclusa +/-  RBV x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Daclatasvir + Sofobuvir +/-  RBV x24 weeks per AASLD/IDSA
                            ($164,220)
                        </entry>
                        <entry>Epclusa x 12 achieved 97% SVR in GT2 DAA experienced non-NS5A</entry>
                    </row>
                </tbody>
            </tgroup>
        </table>
        <table>
            <title>Genotype 3</title>
            <tgroup cols="4">
                <tbody>
                    <row>
                        <entry><emphasis role="bold">Treatment History</emphasis></entry>
                        <entry><emphasis role="bold">Preferred Regimen (Cost)</emphasis></entry>
                        <entry><emphasis role="bold">Alternative Regimen(s)</emphasis></entry>
                        <entry><emphasis role="bold">Comments</emphasis></entry>
                    </row>
                    <row>
                        <entry>Naïve</entry>
                        <entry>Epclusa x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Sofosbuvir + Daclatasvir x 12 weeks
                            ($82,110)
                            ALLY 3 SVR12- 97%  (73/75)
                        </entry>
                        <entry></entry>
                    </row>
                    <row>
                        <entry>Treatment Experienced INF/RBV</entry>
                        <entry>Epclusa + RBV x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Sofosbuvir + Daclatasvir + RBV x 12 weeks
                            ($82,110)
                            ALLY 3 SVR12- 94% (32/34)
                        </entry>
                        <entry>Can omit RBV with Epclusa if no NS5A RAS</entry>
                    </row>
                    <row>
                        <entry>Treamtent Experienced Sofosbuvir/RBV</entry>
                        <entry>Epclusa + RBV x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Daclatasvir + Sofosbuvir + RBV x 24 weeks per AASLD/IDSA
                            ($164,220)
                        </entry>
                        <entry>Epclusa x 12 achieved 85% SVR in GT 3
                            DAA experienced non-NS5A
                        </entry>
                    </row>
                    <row>
                        <entry>Treatment Experienced Harvoni/RBV</entry>
                        <entry>Epclusa + RBV x 12 weeks (if no Y93 mutation)
                            ($45,048.51)
                        </entry>
                        <entry>Epclusa + RBV x 24 weeks (if Y93 mutation is present)
                            ($90,000)
                        </entry>
                        <entry>Unlikely to have Y93 mutation</entry>
                    </row>
                    <row>
                        <entry>Treatment Experienced Daclatasvir or Velpatasvir</entry>
                        <entry>Epclusa + RBV x 24 weeks
                            ($90,000)
                            -          13/16 (81%) SVR overall
                            -          9/11 (82%) with Y93 mutation
                        </entry>
                        <entry></entry>
                        <entry>Patients will almost certainly have the Y93 mutation
                            SHOULD wait for new drugs if possible
                        </entry>
                    </row>
                </tbody>
            </tgroup>
        </table>
        <table>
            <title>Genotype 4</title>
            <tgroup cols="4">
                <tbody>
                    <row>
                        <entry><emphasis role="bold">Treatment History</emphasis></entry>
                        <entry><emphasis role="bold">Preferred Regimen (Cost)</emphasis></entry>
                        <entry><emphasis role="bold">Alternative Regimen(s)</emphasis></entry>
                        <entry><emphasis role="bold">Comments</emphasis></entry>
                    </row>
                    <row>
                        <entry>Naïve</entry>
                        <entry>Zepatier x 12 weeks
                            ($15,522)
                        </entry>
                        <entry>Harvoni x 12 weeks
                            ($15,669)
                        </entry>
                        <entry></entry>
                    </row>
                    <row>
                        <entry>Treatment experienced
                            INF/RBV
                        </entry>
                        <entry>Harvoni x 12 weeks
                            ($15,669)
                        </entry>
                        <entry>Zepatier + Ribavirin x 16 weeks
                            ($20,892)
                            
                            Paritaprevir/Ritonavir/Ombitasvir + RBV (no Dasabuvir) x 12 weeks
                            ($15,522)
                        </entry>
                        <entry></entry>
                    </row>
                    <row>
                        <entry>DAA treatment experienced</entry>
                        <entry>Zepatier + Sofosbuvir + RBV x 12 to 16 weeks</entry>
                        <entry></entry>
                        <entry>Obtain resistance testing
                            Consider waiting for future options if no urgency to treat
                        </entry>
                    </row>
                </tbody>
            </tgroup>
        </table>
        <table>
            <title>Genotype 5 and 6</title>
            <tgroup cols="4">
                <tbody>
                    <row>
                        <entry><emphasis role="bold">Treatment History</emphasis></entry>
                        <entry><emphasis role="bold">Preferred Regimen(s)</emphasis></entry>
                        <entry><emphasis role="bold">Alternative Regimen(s)</emphasis></entry>
                        <entry><emphasis role="bold">Comments</emphasis></entry>
                    </row>
                    <row>
                        <entry>Treatment Naïve and Experienced</entry>
                        <entry>Harvoni x 12
                            ($15,669)
                        </entry>
                        <entry>Epclusa x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Limited data</entry>
                    </row>
                </tbody>
            </tgroup>
        </table>
        <para>Patients With Cirrhosis:</para>
        <table>
            <title>Genotype 1</title>
            <tgroup cols="4">
                <tbody>
                    <row>
                        <entry><emphasis role="bold">Treatment History</emphasis></entry>
                        <entry><emphasis role="bold">Preferred Regimen (Cost)</emphasis></entry>
                        <entry><emphasis role="bold">Alternative Regimen(s)</emphasis></entry>
                        <entry><emphasis role="bold">Comments</emphasis></entry>
                    </row>
                    <row>
                        <entry>Naïve</entry>
                        <entry>Genotype 1a:
                            Harvoni + RBV x 12 weeks
                            ($15,585.36)
                            
                            Genotype 1b:
                            Zepatier x 12 weeks
                            ($15,436.68)
                        </entry>
                        <entry>Genotype 1a:
                            Zepatier  x12 weeks in patients without baseline NS5A RAV
                            ($15,436.68)
                            
                            Zepatier + Ribavirin x 16 weeks in patients with baseline NS5A RAV
                            ($20,582.24)
                            
                            Genotype 1b:
                            Harvoni x 12 weeks
                            ($15,585.36)
                            
                            Genotype 1:
                            Epclusa x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Consider Zepatier for patients who are not candidates for Harvoni: -
                            CrCl &lt;30ml/min - Drug interactions (amiodarone) - Patients who are on
                            high dose PPI and cannot hold PPI while on treatment </entry>
                    </row>
                    <row>
                        <entry>Treatment Experienced
                            INF/RBV
                        </entry>
                        <entry>Genotype 1a:
                            Harvoni + RBV x 12 weeks
                            ($15,585.36)
                            
                            Genotype 1b:
                            Zepatier x 12 weeks
                            ($15,436.68)
                        </entry>
                        <entry>Genotype 1a:
                            Zepatier  x12 weeks in patients without baseline NS5A RAV
                            ($15,436.68)
                            
                            Zepatier + Ribavirin x 16 weeks in patients with baseline NS5A RAV
                            ($20,582.24)
                            
                            Genotype 1b:
                            Harvoni + RBV  x 12 weeks
                            ($15,585.36)
                            
                            Genotype 1:
                            Epclusa x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry></entry>
                    </row>
                    <row>
                        <entry>Treatment Experienced
                            INF/RBV/PI
                        </entry>
                        <entry>Genotype 1a:
                            Harvoni + RBV x 12 weeks
                            ($15,585.36)
                            
                            Genotype 1b:
                            Zepatier +Ribavirin x 12 weeks
                            ($15,436.68)
                        </entry>
                        <entry>Genotype 1a:
                            Zepatier + Ribavirin x12 weeks in patients without baseline NS5A RAV
                            ($15,436.68)
                            
                            Zepatier + Ribavirin x 16 weeks in patients with baseline NS5A RAV
                            ($20,582.24)
                            
                            Genotype 1b:
                            Harvoni + RBV x 12 weeks
                            ($15,585.36)
                        </entry>
                        <entry></entry>
                    </row>
                    <row>
                        <entry>DAA Treatment Experienced
                            *Non NS5A*
                        </entry>
                        <entry>Harvoni + RBV x 24 weeks
                            ($31,170.72)
                            
                            Epclusa + RBV x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry></entry>
                        <entry>Likely will not need resistance testing</entry>
                    </row>
                    <row>
                        <entry>DAA Treatment Experienced *NS5A*</entry>
                        <entry>Zepatier + Sofosbuvir + RBV x 12 to 16 weeks (Consider 16 weeks for Y93 mutation)
                            
                            Epclusa + RBV x 24 weeks (if strong NS5A mutation is present)
                        </entry>
                        <entry>Harvoni + RBV x 24 weeks (if no NS5A mutation)
                            ($31,170.72)
                            
                            Epclusa + RBV x 12 weeks (if no NS5A mutation)
                            ($45,048.51)
                        </entry>
                        <entry>Obtain resistance testing (both PI and NS5A)
                            Consider waiting for future options if no urgency to treat
                            Treatment option depends on duration of previous treatment, presence of NS5A RAS, and what kind/number of NS5A RAS
                        </entry>
                    </row>
                    <row>
                        <entry>CrCl &lt; 30 mL/min or ESRD</entry>
                        <entry>Genotype 1a:
                            Zepatier  x12 weeks in patients without baseline NS5A RAV
                            ($15,522)
                            Zepatier + Ribavirin x 16 weeks in patients with baseline NS5A RAV
                            ($20,892)
                            
                            Genotype 1b:
                            Zepatier x 12 weeks
                            ($15,522)
                        </entry>
                        <entry>Genotype 1a:
                            Viekira Pack  + Low Dose RBV x 12 weeks
                            ($15,522.36)
                            
                            Genotype 1b:
                            Viekira Pack x 12 weeks
                            ($15,522.36)
                        </entry>
                        <entry>RBV 200mg daily if used in CKD/ESRD patients</entry>
                    </row>
                    <row>
                        <entry>Decompensated Cirrhosis</entry>
                        <entry>Harvoni + RBV x 12 weeks
                            ($15,585.36)
                            
                            Epclusa + RBV x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Harvoni x 24 weeks
                            ($31,338)
                            
                            Epclusa x 12 weeks
                            ($45,048.51)
                            -          44/50 (88%) in GT1a
                            -          16/18 (89%) in GT1b
                        </entry>
                        <entry></entry>
                    </row>
                </tbody>
            </tgroup>
        </table>
        <table>
            <title>Genotype 2</title>
            <tgroup cols="4">
                <tbody>
                    <row>
                        <entry><emphasis role="bold">Treatment History</emphasis></entry>
                        <entry><emphasis role="bold">Preferred Regimen (Cost)</emphasis></entry>
                        <entry><emphasis role="bold">Alternative Regimen(s)</emphasis></entry>
                        <entry><emphasis role="bold">Comments</emphasis></entry>
                    </row>
                    <row>
                        <entry>Naïve</entry>
                        <entry>Epclusa x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Harvoni + RBV x 16 weeks
                            ($20,780.48)
                        </entry>
                        <entry></entry>
                    </row>
                    <row>
                        <entry>Treatment experienced
                            INF/RBV
                        </entry>
                        <entry>Epclusa x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Harvoni + RBV x 16 weeks
                            ($20,780.48)
                        </entry>
                        <entry></entry>
                    </row>
                    <row>
                        <entry>Treatment Experienced
                            Sofosbuvir/RBV
                        </entry>
                        <entry>Epclusa + RBV x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Daclatasvir + Sofobuvir +/-  RBV x24 weeks per AASLD/IDSA
                            ($164,220)
                        </entry>
                        <entry>Epclusa x 12 achieved 97% SVR in GT2 DAA experienced non-NS5A</entry>
                    </row>
                    <row>
                        <entry>Decompensated Cirrhosis</entry>
                        <entry>Epclusa +/- RBV x 12 weeks
                            -          4/4 without RBV
                            -          4/4 with RBV
                        </entry>
                        <entry></entry>
                        <entry></entry>
                    </row>
                </tbody>
            </tgroup>
        </table>
        <table>
            <title>Genotype 3</title>
            <tgroup cols="4">
                <tbody>
                    <row>
                        <entry><emphasis role="bold">Treatment History</emphasis></entry>
                        <entry><emphasis role="bold">Preferred Regimen (Cost)</emphasis></entry>
                        <entry><emphasis role="bold">Alternative Regimen(s)</emphasis></entry>
                        <entry><emphasis role="bold">Comments</emphasis></entry>
                    </row>
                    <row>
                        <entry>Naïve</entry>
                        <entry>Epclusa + RBV  x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Daclatasvir + Sofosbuvir + Ribavirin x 12 weeks
                            ($82,110)
                        </entry>
                        <entry>Can omit RBC with Epclusa if no NS5A RAS</entry>
                    </row>
                    <row>
                        <entry>Treatment experienced
                            INF/RBV
                        </entry>
                        <entry>Epclusa + RBV x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Daclatasvir + Sofosbuvir + Ribavirin x 12
                            ($82,110)
                        </entry>
                        <entry>Can omit RBV with Epclusa if no NS5A RAS</entry>
                    </row>
                    <row>
                        <entry>Treatment Experienced
                            Sofosbuvir/RBV
                        </entry>
                        <entry>Epclusa + RBV x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Daclatasvir + Sofosbuvir + Ribavirin x 24 weeks
                            ($164,220); Per AASLD)
                        </entry>
                        <entry>Epclusa x 12 achieved 85% SVR in GT 3
                            DAA experienced non-NS5A
                        </entry>
                    </row>
                    <row>
                        <entry>Treatment Experienced
                            Harvoni/RBV
                        </entry>
                        <entry>Epclusa + RBV x 12 weeks (if no Y93 mutation)
                            ($45,048.51)
                        </entry>
                        <entry>Epclusa + RBV x 24 weeks (if Y93 mutation is present or decomp cirrhosis)
                            ($90,000)
                        </entry>
                        <entry></entry>
                    </row>
                    <row>
                        <entry>Treatment Experienced
                            Daclatasvir or Velpatasvir
                        </entry>
                        <entry>Epclusa + RBV x 24 weeks
                            ($90,000)
                            -          13/16 (81%) SVR overall
                            -          9/11 (82%) with Y93 mutation
                        </entry>
                        <entry></entry>
                        <entry>Patients will almost certainly have the Y93 mutation
                            SHOULD wait for new drugs if possible
                        </entry>
                    </row>
                    <row>
                        <entry>Decompensated Cirrhosis</entry>
                        <entry>Epclusa + RBV x 12 weeks</entry>
                        <entry></entry>
                        <entry></entry>
                    </row>
                </tbody>
            </tgroup>
        </table>
        <table>
            <title>Genotype 4</title>
            <tgroup cols="4">
                <tbody>
                    <row>
                        <entry><emphasis role="bold">Treatment History</emphasis></entry>
                        <entry><emphasis role="bold">Preferred Regimen (Cost)</emphasis></entry>
                        <entry><emphasis role="bold">Alternative Regimen(s)</emphasis></entry>
                        <entry><emphasis role="bold">Comments</emphasis></entry>
                    </row>
                    <row>
                        <entry>Naïve</entry>
                        <entry>Zepatier x 12 weeks
                            ($15,436.68)
                        </entry>
                        <entry>Harvoni x 12 weeks
                            ($15,585.36)
                        </entry>
                        <entry>Omit dasabuvir from Viekira pack when using it to treat GT 4</entry>
                    </row>
                    <row>
                        <entry>Treatment experienced
                            INF/RBV
                        </entry>
                        <entry>Harvoni x 12 weeks
                            ($15,585.36)
                        </entry>
                        <entry>Zepatier + Ribavirin x 16 weeks
                            ($20,582.24)
                            
                            Paritaprevir/Ritonavir/Ombitasvir + RBV x 12 weeks
                            ($15,522.36)
                        </entry>
                        <entry>Omit dasabuvir from Viekira pack when using it to treat GT 4</entry>
                    </row>
                    <row>
                        <entry>DAA treatment experienced</entry>
                        <entry>Zepatier + Sofosbuvir + RBV x 12 to 16 weeks</entry>
                        <entry></entry>
                        <entry>Obtain resistance testing
                            Consider waiting for future options if no urgency to treat
                        </entry>
                    </row>
                    <row>
                        <entry>Naïve CrCl 30 mL/min or ESRD</entry>
                        <entry>Zepatier x 12 weeks
                            ($15,522)
                        </entry>
                        <entry>Viekira Pack + RBV  x 12 weeks
                            ($15,522.36)
                        </entry>
                        <entry>RBV 200mg daily if used in CKD/ESRD patients</entry>
                    </row>
                    <row>
                        <entry>Decompensated Cirrhosis</entry>
                        <entry>Harvoni + RBV x 12 weeks
                            ($15,585.36)
                        </entry>
                        <entry>Epclusa +/- RBV x 12 weeks
                            ($45,048.51)
                            -          4/4 without RBV
                            -          2/2 with RBV
                        </entry>
                        <entry></entry>
                    </row>
                </tbody>
            </tgroup>
        </table>
        <table>
            <title>Genotype 5 and 6</title>
            <tgroup cols="4">
                <tbody>
                    <row>
                        <entry><emphasis role="bold">Treatment History</emphasis></entry>
                        <entry><emphasis role="bold">Preferred Regimen (Cost)</emphasis></entry>
                        <entry><emphasis role="bold">Alternative Regimen(s)</emphasis></entry>
                        <entry><emphasis role="bold">Comments</emphasis></entry>
                    </row>
                    <row>
                        <entry>Treatment Naïve and Experienced</entry>
                        <entry>Harvoni x 12 weeks
                            ($15,585.36)
                        </entry>
                        <entry>Epclusa x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry>Limited data</entry>
                    </row>
                    <row>
                        <entry>Decompensated Cirrhosis</entry>
                        <entry>Harvoni + RBV x 12 weeks
                            ($15,585.36)
                        </entry>
                        <entry>Epclusa + RBV x 12 weeks
                            ($45,048.51)
                        </entry>
                        <entry></entry>
                    </row>
                </tbody>
            </tgroup>
        </table>
        <para>Figures A.12 through A.19 for the Hepatitis C - Ledipasvir/Sofosbuvir - Order Set are
            from the Greater Los Angeles VAMC.</para>
        <figure>
            <title>Reminder Dialog Template: Hepatitis C Clinic Subjective Objective Assessment Plan
                (SOAP)  (I &amp;II combined) (Image 1 of 8)</title>
            <mediaobject>
                <alt>Screenshot of the Hepatitis C Clinic Note including the History of Present
                    Illness, Review of Systems, and Past Medical History.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig12ClinicNote.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Reminder Dialog Template: Hepatitis C Clinic Subjective Objective Assessment Plan
                (SOAP)  (I &amp;II combined) (Image 2 of 8)</title>
            <mediaobject>
                <alt>Continuation of the screenshot of the Hepatitis C Clinic Note including
                    Medications: Active Outpatient Medications (excluding Supplies).</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig13Medications.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Reminder Dialog Template: Hepatitis C Clinic Subjective Objective Assessment Plan
                (SOAP)  (I &amp;II combined) (Image 3 of 8)</title>
            <mediaobject>
                <alt>Screenshot of the Hepatitis C Clinic Note including Allergies and Social
                    History.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig14SocialHistory.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Reminder Dialog Template: Hepatitis C Clinic Subjective Objective Assessment Plan
                (SOAP)  (I &amp;II combined) (Image 4 of 8)</title>
            <mediaobject>
                <alt>Screenshot of the Hepatitis C Clinic Note including Physical Exam list of the
                    following 1. General, 2. Heent, 3. Cardiovascular, 4. Lungs, 5. Abdomen, 6.
                    Exremities; and Labs list of CBC, Liver Studies and Chemistries, ALK
                    Phosphatase, and Direct Bilirubin.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig15PhysicalExamandLabs.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Reminder Dialog Template: Hepatitis C Clinic Subjective Objective Assessment Plan
                (SOAP)  (I &amp;II combined) (Image 5 of 8)</title>
            <mediaobject>
                <alt>Screenshot of the Hepatitis C Clinic Note continuing the list of Labs as well
                    as Imaging selections.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig16Imaging.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Reminder Dialog Template: Hepatitis C Clinic Subjective Objective Assessment Plan
                (SOAP)  (I &amp;II combined) (Image 6 of 8)</title>
            <mediaobject>
                <alt>Screenshot of the Hepatitis C Clinic Note including Liver Body Results, EGD
                    Results, and Assessment and Plan.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig17AssessmentandPlan.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Reminder Dialog Template: Hepatitis C Clinic Subjective Objective Assessment Plan
                (SOAP)  (I &amp;II combined) (Image 7 of 8)</title>
            <mediaobject>
                <alt>Screenshot of the Hepatitis C Clinic Note including Fibrosis Stage (Metavir
                    Score), Prior Treatments, Medical Decision Making and Vaccinations needed.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig18FibrosisStage.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <figure>
            <title>Reminder Dialog Template: Hepatitis C Clinic Subjective Objective Assessment Plan
                (SOAP)  (I &amp;II combined) (Image 8 of 8)</title>
            <mediaobject>
                <alt>Screenshot of the Hepatitis C Clinic Note including the Recommended laboratory
                    follow-up while on therapy.</alt>
                <imageobject>
                    <imagedata align="center"
                        fileref="images/Fig19LaboratoryFollow-Up.png"/>
                </imageobject>
            </mediaobject>
        </figure>
        <para>APRI Score:
            <link>http://www.hepatitisc.uw.edu/page/clinical-calculators/apri</link></para>
        <para>CTP Score:
            <link>http://www.hepatitisc.uw.edu/page/clinical-calculators/ctp</link></para>
        <para>MELD Score:
            <link>http://www.hepatitisc.uw.edu/page/clinical-calculators/meld</link></para>
        <para>VA hepatitis website: <link>http://www.hepatitis.va.gov/</link></para>
    </appendix>
    <appendix>
        <title>Clinical Guidelines</title>
        <para>The below links are from the Greater Los Angeles VAMC. </para>
        <para>Aspartate aminotransferase (AST) to Platelet Ratio Index (APRI) Score:
            http://www.hepatitisc.uw.edu/page/clinical-calculators/apri </para>
        <para>CTP Score: http://www.hepatitisc.uw.edu/page/clinical-calculators/ctp </para>
        <para>Model for End-Stage Liver Disease (MELD) Score:
            http://www.hepatitisc.uw.edu/page/clinical-calculators/meld </para>
        <para>VA hepatitis website: http://www.hepatitis.va.gov/ </para>
    </appendix>
    <appendix>
        <title>Basic Laboratory Panel Definition</title>
        <itemizedlist mark="none">
            <listitem>
                <para>Blood Urea Nitrogen</para>
            </listitem>
            <listitem>
                <para>Calcium</para>
            </listitem>
            <listitem>
                <para>Chloride</para>
            </listitem>
            <listitem>
                <para>CO2 (Carbon Dioxide, Bicarbonate)</para>
            </listitem>
            <listitem>
                <para>Creatinine</para>
            </listitem>
            <listitem>
                <para>Glucose</para>
            </listitem>
            <listitem>
                <para>Potassium</para>
            </listitem>
            <listitem>
                <para>Sodium</para>
            </listitem>
        </itemizedlist>
    </appendix>
    <glossary>
        <title>Acronyms</title>
    </glossary>
</book>
